Oncoinvent ASA (FRA:7BG) Beginning Cash Position: €16.28 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7BG Oncoinvent ASA FRA:7BG
56 GF Score
Price €8.54
GF Value €20.39
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Oncoinvent ASA Beginning Cash Position?

Oncoinvent ASA FRA:7BG +8.38% 56 Beginning Cash Position is €16.28 Mil as of Jun. 2026. GuruFocus rates FRA:7BG with a GF Score™ of 56/100 and a GF Value™ of €20.39 (Possible Value Trap). The stock has 5 warning signs investors should review.

Oncoinvent ASA's Beginning Cash Position for the quarter that ended in Jun. 2026 was €16.28 Mil.

Oncoinvent ASA's quarterly Beginning Cash Position declined from Jun. 2025 (€11.75 Mil) to Dec. 2025 (€11.27 Mil) but then increased from Dec. 2025 (€11.27 Mil) to Jun. 2026 (€16.28 Mil).

Oncoinvent ASA's annual Beginning Cash Position declined from Dec. 2023 (€13.11 Mil) to Dec. 2024 (€2.42 Mil) but then increased from Dec. 2024 (€2.42 Mil) to Dec. 2025 (€15.80 Mil).

Oncoinvent ASA Beginning Cash Position Related Terms

Oncoinvent ASA Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Beginning Cash Position Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.11 41.72 13.11 2.42 15.80

Oncoinvent ASA Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.69 3.04 11.75 11.27 16.28
FRA:7BG
56GF Score
Oncoinvent ASA FRA:7BG
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €16.28 Mil mean?
Oncoinvent ASA (FRA:7BG) has a Beginning Cash Position of €16.28 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Beginning Cash Position too high?
Oncoinvent ASA's current Beginning Cash Position is €16.28 Mil. Overall, Oncoinvent ASA has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Beginning Cash Position compare to VRTX and REGN?
Oncoinvent ASA's Beginning Cash Position of €16.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Beginning Cash Position is €16.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Based on GuruFocus' analysis, Oncoinvent ASA (FRA:7BG) is currently considered Possible Value Trap. The stock's GF Value™ is €20.39, compared to a current price of €8.54 — trading 58.1% below its estimated fair value. The current Beginning Cash Position is €16.28 Mil. Oncoinvent ASA's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Oncoinvent ASA (FRA:7BG), the current Beginning Cash Position is €16.28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (FRA:7BG) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of €8.54 is trading 58.1% below its estimated GF Value™ of €20.39. GuruFocus considers Oncoinvent ASA to be Possible Value Trap.

Key valuation signals for FRA:7BG:

  • Beginning Cash Position: €16.28 Mil
  • GF Value™: €20.39 vs. price of €8.54 (58.1% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the FRA:7BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Other Exchanges ONCIN:Norway0RU5:UK
Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
56GF Score

Get the complete analysis for FRA:7BG

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.54
Price
€20.39
GF Value